Metabolic syndrome and prostate cancer: a review.
Clin Oncol (R Coll Radiol)
; 21(3): 183-91, 2009 Apr.
Article
en En
| MEDLINE
| ID: mdl-19111451
ABSTRACT
Androgen deprivation therapy is widely used in a number of different settings in the treatment of prostate cancer. This overview will look at the current evidence for the potential development of metabolic syndrome and cardiovascular disease as a consequence of this therapy, and highlight strategies aimed at their prevention. The relationship between metabolic syndrome and prostate cancer development will also be examined.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Síndrome Metabólico
Idioma:
En
Revista:
Clin Oncol (R Coll Radiol)
Asunto de la revista:
NEOPLASIAS
Año:
2009
Tipo del documento:
Article